Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib and Adebrelimab with Radiotherapy in MSS mCRC
NCT06613113Recruiting
- Sponsor
- Ningbo Medical Centre Lihuili Hospital
- Start
- Aug 2024
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Open-label, single-arm trial of adebrelimab in metastatic colorectal cancer (mCRC), sponsored by Ningbo Medical Centre Lihuili Hospital. Primary endpoint: Objective Response Rate at 1 year. Started Aug 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06613113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613113.